Recent Updates
Recently added Catalysts

denufosol tetrasodium Intravitreal

Phase 1

Retinal Detachment | Small molecule | Ophthalmology |Merck & Company, Inc.|Last Updated: Oct 9, 2015

Target and mechanism

ModalitySmall molecule

Also known as denufosol tetrasodium (INS37217) Intravitreal Injection

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment14

FDA Designations

No designations recorded

Clinical trial landscape

denufosol tetrasodium Intravitreal · 1 trial · 1 indication

Phase 1 1
NCT00210067A Study in Subjects With Retinal DetachmentRetinal Detachment
COMPLETED14 Analytics
PHASE1COMPLETED
A Study in Subjects With Retinal Detachment
Retinal Detachment
NCT0021006714
Unlock trial analytics

Study Endpoints

Primary Endpoints

tolerability

Secondary Endpoints

pharmacological activity
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
denufosol tetrasodium (INS37217) Intravitreal InjectionDRUG -
Unlock Study Design Details

Eligibility Criteria

Healthy VolunteersNo

Inclusion Criteria: * have macula-on or macula-off rhegmatogenous retinal detachment * are eligible for pneumatic retinopexy, with identifiable retinal breaks * are phakic or pseudo-phakic Exclusion Criteria: * have detachments not of a rhegmatogenous nature * currently have blood in the vitreous...

Unlock Eligibility Criteria